Biosimilars in Europe

This reprint examines regulatory, pricing and reimbursement issues related to the market access and uptake of off-patent biologics, biosimilars, next-generation biologics and competing innovative medicines in European countries.

Kaydedildi:
Detaylı Bibliyografya
Diğer Yazarlar: Vulto, Arnold G. (Editör), Simoens, Steven (Editör), Huys, Isabelle (Editör)
Materyal Türü: Elektronik Kitap Bölümü
Dil:İngilizce
Baskı/Yayın Bilgisi: Basel MDPI - Multidisciplinary Digital Publishing Institute 2023
Konular:
Online Erişim:DOAB: download the publication
DOAB: description of the publication
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_96784
005 20230202
003 oapen
006 m o d
007 cr|mn|---annan
008 20230202s2023 xx |||||o ||| 0|eng d
020 |a books978-3-0365-6574-3 
020 |a 9783036565750 
020 |a 9783036565743 
040 |a oapen  |c oapen 
024 7 |a 10.3390/books978-3-0365-6574-3  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a M  |2 bicssc 
072 7 |a KNDP  |2 bicssc 
100 1 |a Vulto, Arnold G.  |4 edt 
700 1 |a Simoens, Steven  |4 edt 
700 1 |a Huys, Isabelle  |4 edt 
700 1 |a Vulto, Arnold G.  |4 oth 
700 1 |a Simoens, Steven  |4 oth 
700 1 |a Huys, Isabelle  |4 oth 
245 1 0 |a Biosimilars in Europe 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2023 
300 |a 1 electronic resource (188 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a This reprint examines regulatory, pricing and reimbursement issues related to the market access and uptake of off-patent biologics, biosimilars, next-generation biologics and competing innovative medicines in European countries. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Medicine  |2 bicssc 
650 7 |a Pharmaceutical industries  |2 bicssc 
653 |a infliximab 
653 |a etanercept 
653 |a TNFα inhibitors 
653 |a biologics 
653 |a biosimilars 
653 |a Germany 
653 |a policies 
653 |a incentives 
653 |a uptake 
653 |a market dynamics 
653 |a biosimilar market 
653 |a biosimilar/supply and distribution 
653 |a biosimilar sustainability 
653 |a Delphi technique 
653 |a pricing 
653 |a reimbursement 
653 |a utilization 
653 |a biosimilar 
653 |a biological 
653 |a information 
653 |a education 
653 |a communication 
653 |a patient 
653 |a Europe 
653 |a adalimumab 
653 |a biosimilarity assessment 
653 |a quality attributes (QAs) 
653 |a potentially critical quality attributes (pCQAs) 
653 |a European public assessment reports (EPARs) 
653 |a clinical governance 
653 |a Spain 
653 |a barriers 
653 |a regulatory 
653 |a review 
653 |a approval 
653 |a clinical 
653 |a queries 
653 |a regulatory science 
653 |a budget impact analysis 
653 |a savings 
653 |a pharmaceutical spending 
653 |a cost containment 
653 |a reference biological 
653 |a competitive market 
653 |a Belgium 
653 |a trastuzumab 
653 |a intravenous 
653 |a subcutaneous 
653 |a HER2-positive breast cancer 
653 |a drug costs 
653 |a healthcare costs 
653 |a cost simulation 
653 |a tender 
653 |a procurement 
653 |a off-patent 
653 |a award criteria 
653 |a switching 
653 |a interchangeability 
653 |a sustainability 
653 |a competition 
653 |a n/a 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/6730  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/96784  |7 0  |z DOAB: description of the publication